562 related articles for article (PubMed ID: 22886134)
1. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
[TBL] [Abstract][Full Text] [Related]
2. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.
Cai J; Yang P; Zhang C; Zhang W; Liu Y; Bao Z; Liu X; Du W; Wang H; Jiang T; Jiang C
Oncotarget; 2014 May; 5(9):2551-61. PubMed ID: 24810474
[TBL] [Abstract][Full Text] [Related]
3. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
[TBL] [Abstract][Full Text] [Related]
4. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
[TBL] [Abstract][Full Text] [Related]
5. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
Cryan JB; Haidar S; Ramkissoon LA; Bi WL; Knoff DS; Schultz N; Abedalthagafi M; Brown L; Wen PY; Reardon DA; Dunn IF; Folkerth RD; Santagata S; Lindeman NI; Ligon AH; Beroukhim R; Hornick JL; Alexander BM; Ligon KL; Ramkissoon SH
Oncotarget; 2014 Sep; 5(18):8083-92. PubMed ID: 25257301
[TBL] [Abstract][Full Text] [Related]
6. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
7. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.
Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M
Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
Jain S; Gupta P; Shankar KB; Singh R; Siraj F
J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
[TBL] [Abstract][Full Text] [Related]
9. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H
Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205
[TBL] [Abstract][Full Text] [Related]
10. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
[TBL] [Abstract][Full Text] [Related]
11. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
[TBL] [Abstract][Full Text] [Related]
14. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Abedalthagafi M; Phillips JJ; Kim GE; Mueller S; Haas-Kogen DA; Marshall RE; Croul SE; Santi MR; Cheng J; Zhou S; Sullivan LM; Martinez-Lage M; Judkins AR; Perry A
Mod Pathol; 2013 Nov; 26(11):1425-32. PubMed ID: 23765250
[TBL] [Abstract][Full Text] [Related]
15. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
16. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
[TBL] [Abstract][Full Text] [Related]
17. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
18. A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.
Borodovsky A; Meeker AK; Kirkness EF; Zhao Q; Eberhart CG; Gallia GL; Riggins GJ
J Neurooncol; 2015 Feb; 121(3):479-87. PubMed ID: 25471051
[TBL] [Abstract][Full Text] [Related]
19. Genetic Analysis of Diffuse High-Grade Astrocytomas in Infancy Defines a Novel Molecular Entity.
Gielen GH; Gessi M; Buttarelli FR; Baldi C; Hammes J; zur Muehlen A; Doerner E; Denkhaus D; Warmuth-Metz M; Giangaspero F; Lauriola L; von Bueren AO; Kramm CM; Waha A; Pietsch T
Brain Pathol; 2015 Jul; 25(4):409-17. PubMed ID: 25231549
[TBL] [Abstract][Full Text] [Related]
20. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
